Skip to Content
You are currently on the new version of our website. Access the old version .
PathogensPathogens
  • Article
  • Open Access

16 June 2026

13 Pages

Development of Peptide Entry Inhibitors Targeting the Endosomal Receptor NPC1 Binding Site of Orthoebolavirus

,
,
,
,
,
,
,
and
1
School of Veterinary Medicine and Biomedical Sciences, Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE 68588, USA
2
Texas Biomedical Research Institute, 8715 W. Military Drive, San Antonio, TX 78227, USA
3
National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02115, USA
4
Nonclinical Pathology Services, LLC, 5920 Clubhouse Pointe Dr., Medina, OH 44256, USA

Abstract

Orthoebolavirus causes severe Ebola virus disease (EVD) and deadly outbreaks in humans. This infection occurs through macropinocytosis and trafficking to late endosomes or lysosomes that utilize the receptor Niemann–Pick C1 (NPC1) to enter the cell cytoplasm. We designed peptide inhibitors based on the NPC1 receptor to target the NPC1 binding site to block viral entry. The results indicated that the ligand-based peptide inhibitors showed potent inhibition activities in vitro studies against pseudotyped or replication-competent Orthoebolavirus. Therefore, we further evaluated one of them in a mouse model challenged with mice-adapted Ebola viruses, which showed some protection efficacy compared with the control group. This study suggests that ligand-based peptides are encouraging inhibitors in the development of inhibitors against Ebola virus infection.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.